RxDoctor Payments Data

Mark Byron, MD

Urology · Jesup, GANPI 1154315877

Payments from drug & device makers

$1,126in general payments, 2019–2025

Across 31 payments — averaging $36.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$571
  • Boston Scientific$216
  • Procept Biorobotics Corporation$169
  • Astellas Pharma US Inc$82
  • Myovant Sciences Inc.$37
  • Coloplast$20
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$1,04793%
  • Education$797%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,126 in reported general payments places this provider in the 25th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$569,960
Medicare patients
1,036
Services billed
6,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide24$337,740
GemtesaVibegron364$273,758
MyrbetriqMirabegron143$100,368
Doxazosin Mesylate914$14,216
Tamsulosin Hcl1,078$14,102
Methenamine Hippurate123$10,672
Trimethoprim114$9,754
Fesoterodine Fumarate ErFesoterodine Fumarate111$9,573
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst503$8,909
Tolterodine Tartrate ErTolterodine Tartrate80$7,339
Oxybutynin Chloride ErOxybutynin Chloride403$6,945
Finasteride390$5,014
Ciprofloxacin Hcl389$4,426
Solifenacin Succinate64$3,814
Bicalutamide86$3,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$82$438,108167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 369 urology providers in Georgia.

Other urology in Jesup

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →